Estrogen Administration for the Treatment of NASH in Postmenopausal Women
雌激素治疗绝经后妇女 NASH
基本信息
- 批准号:10307423
- 负责人:
- 金额:$ 73.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:ADD-1 proteinAgeAnimalsBiopsyCD8-Positive T-LymphocytesCell LineageCellsCharacteristicsCirrhosisDataDevelopmentDiseaseDisease ProgressionDoseDouble-Blind MethodECM receptorEndocrinologyEpidemicEstradiolEstrogen Replacement TherapyEstrogen TherapyEstrogensFDA approvedFatty acid glycerol estersFibrosisGene Expression ProfileGenerationsGenesGenetic TranscriptionGoldHepaticHigh PrevalenceHumanIL17 Signaling PathwayImmuneImmunologicsImmunologyInflammationLipidsLiverLiver FibrosisLiver diseasesLobularLow PrevalenceMachine LearningMagnetic Resonance SpectroscopyManipulative TherapiesMenopauseMetabolicMetabolic DiseasesMetabolic PathwayMethodsMicroscopyObesityOvariectomyPathogenesisPathologicPathway interactionsPlacebosPlayPositioning AttributePostmenopausePre-Clinical ModelPremenopausePrevalencePrevention trialProcessProspective StudiesProtonsRandomizedRattusResearchResearch PersonnelRiskRoleSecondary toTechnologyTestingTissuesUnited StatesWomanWorkclinically significantdesigndouble-blind placebo controlled trialeffective therapyelastographyexperiencefibrogenesisimmunoregulationimprovedintrahepaticlipid biosynthesisliver biopsyliver imagingliver transplantationmacrophagemenmultidisciplinarynew therapeutic targetnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnoveloxidationpatient subsetsplacebo controlled studyprimary endpointprospectiverandomized placebo controlled studyresponsesecond harmonicsexsingle-cell RNA sequencingtherapy developmenttranscriptome sequencingtranscriptomicstransdermal estrogen
项目摘要
PROJECT ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide; progression to
non-alcoholic steatohepatitis (NASH) cirrhosis occurs in a subset of patients and is the second leading indication
for liver transplantation in the United States. The factors leading to the development of NAFLD and progression
to nonalcoholic steatohepatitis (NASH), including inflammation and fibrosis, are poorly understood. Moreover,
there is a lack of effective therapies for these disorders. Studies in animals and humans suggest that estrogen
deficiency may be an important mechanism underlying the development of NAFLD and progression to NASH.
However, no prospective, randomized, placebo-controlled studies have examined the impact of estrogen
administration on steatosis, inflammation or fibrosis in postmenopausal women with NASH. Our overall
hypothesis is that low-dose, transdermal estrogen administration will decrease hepatic fat, inflammation and
fibrosis in women with biopsy-proven NASH. Further, we will explore estrogen’s immune and metabolic effects
in the liver, including changes at the single-cell level. Aim 1 will test the hypothesis that estradiol administration
will decrease fibrosis, inflammation and steatosis in women with biopsy-proven NASH. Aim 2 will determine the
impact of estrogen on intrahepatic metabolic pathways and on the transcriptional landscape of intrahepatic
immune cells. We hypothesize that estrogen will decrease fibrogenesis, decrease hepatic de novo lipogenesis,
and increase lipid beta oxidation. These hypotheses will be tested with a rigorously designed, double-blind,
placebo-controlled study of the effects of low-dose transdermal estrogen replacement therapy in
postmenopausal women with NASH. State-of-the-art liver imaging, liver biopsies, whole liver transcriptomics and
unbiased single cell RNAseq by SeqWell will be leveraged to investigate these hypotheses. We have assembled
a team of investigators with extensive research experience in endocrinology (Dr. Miller), NAFLD (Dr. Corey),
liver imaging (Dr. Bredella), and hepatic immunology (Dr. Lauer), which is uniquely positioned to carry out this
multi-disciplinary proposal. Elucidating the effects of low-dose, transdermal estrogen administration on liver
fibrosis, inflammation and steatosis has the potential to further our understanding of this disease process and
identify new therapeutic targets where few currently exist.
项目摘要
非酒精性脂肪肝病 (NAFLD) 是全世界肝病的最常见原因;进展到
非酒精性脂肪性肝炎 (NASH) 肝硬化发生在部分患者中,是第二个主要适应症
在美国进行肝移植。导致 NAFLD 发生和进展的因素
对非酒精性脂肪性肝炎(NASH)的影响,包括炎症和纤维化,人们知之甚少。而且,
这些疾病缺乏有效的治疗方法。对动物和人类的研究表明,雌激素
缺乏可能是 NAFLD 发生和进展为 NASH 的重要机制。
然而,尚无前瞻性、随机、安慰剂对照研究检验雌激素的影响
治疗患有 NASH 的绝经后妇女的脂肪变性、炎症或纤维化。我们的整体
假设是低剂量、透皮雌激素给药会减少肝脏脂肪、炎症和
经活检证实患有 NASH 的女性会出现纤维化。此外,我们将探讨雌激素的免疫和代谢作用
肝脏中的变化,包括单细胞水平的变化。目标 1 将检验雌二醇给药的假设
将减少经活检证实患有 NASH 的女性的纤维化、炎症和脂肪变性。目标 2 将确定
雌激素对肝内代谢途径和肝内转录景观的影响
免疫细胞。我们假设雌激素会减少纤维生成,减少肝脏从头脂肪生成,
并增加脂质β氧化。这些假设将通过严格设计的、双盲的、
低剂量经皮雌激素替代疗法效果的安慰剂对照研究
患有 NASH 的绝经后妇女。最先进的肝脏成像、肝脏活检、全肝脏转录组学和
SeqWell 的无偏单细胞 RNAseq 将用于研究这些假设。我们已经集合了
一个由在内分泌学(Miller 博士)、NAFLD(Corey 博士)方面拥有丰富研究经验的研究人员组成的团队,
肝脏成像(Bredella 博士)和肝脏免疫学(Lauer 博士)在开展这项研究方面具有独特的优势
多学科提案。阐明低剂量经皮雌激素给药对肝脏的影响
纤维化、炎症和脂肪变性有可能进一步加深我们对这种疾病过程的理解,
确定目前很少存在的新治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Miriam Antoinette Bredella其他文献
Miriam Antoinette Bredella的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Miriam Antoinette Bredella', 18)}}的其他基金
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
雌激素治疗绝经后妇女 NASH
- 批准号:
10618224 - 财政年份:2021
- 资助金额:
$ 73.37万 - 项目类别:
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
雌激素治疗绝经后妇女 NASH
- 批准号:
10445293 - 财政年份:2021
- 资助金额:
$ 73.37万 - 项目类别:
Oxytocin as a Neuroendocrine Therapy for Obesity in Youth
催产素作为青少年肥胖症的神经内分泌疗法
- 批准号:
10264930 - 财政年份:2020
- 资助金额:
$ 73.37万 - 项目类别:
Oxytocin as a Neuroendocrine Therapy for Obesity in Youth
催产素作为青少年肥胖症的神经内分泌疗法
- 批准号:
10118294 - 财政年份:2020
- 资助金额:
$ 73.37万 - 项目类别:
Oxytocin as a Neuroendocrine Therapy for Obesity in Youth
催产素作为青少年肥胖症的神经内分泌疗法
- 批准号:
10435539 - 财政年份:2020
- 资助金额:
$ 73.37万 - 项目类别:
Bone Metabolism in Adolescents Undergoing Bariatric Surgery
接受减肥手术的青少年的骨代谢
- 批准号:
9897530 - 财政年份:2017
- 资助金额:
$ 73.37万 - 项目类别:
Bone Metabolism in Adolescents UndergoingBariatric Surgery
接受减肥手术的青少年的骨代谢
- 批准号:
10115703 - 财政年份:2017
- 资助金额:
$ 73.37万 - 项目类别:
Bone Metabolism in Adolescents Undergoing Bariatric Surgery
接受减肥手术的青少年的骨代谢
- 批准号:
9301775 - 财政年份:2017
- 资助金额:
$ 73.37万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 73.37万 - 项目类别:
Research Grant